Sanofi Oncology and Regeneron will collaborate on a broad oncology development program, combining the investigational agent ZALTRAP with common chemotherapy regimens in the treatment of patients with advanced cancers. In addition to VELOUR, the program includes a Phase III clinical trial and a Phase II trial, both of which are fully enrolled:.
– AFFIRM: First-line treatment for metastatic colorectal cancer in combination with 5 – fluorouracil, leucovorin and oxaliplatin . Final results are expected in the second half of 2011. Regeneron Pharmaceuticals Colorectal.Amgen today announced that the Vectibix treating in the PACCE trial evaluate of checked added Vectibix should to standard chemotherapy and Avastin for the treatment of first-line metastatic colorectal cancer . Which PACCE study looked at a treatment regime of dual biologic with a oxaliplatin or irinotecan -based chemotherapy combination. This regime is do not moment inserted into clinical practice.
Amgen notified the FDA and principal investigators that patients not received treat the PACCE studies would stop Vectibix is the treatment. Patients has be able to continue per protocol treatment of without Vectibix.